Drug intelligence / Profile preview

nogapendekin alfa inbakicept + nivolumab + ipilimumab

Development stage: Unknown
Lead developer: ImmunityBio
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Subcutaneous, Intravenous

Overview

Nogapendekin alfa inbakicept + nivolumab + ipilimumab is a combination immunotherapy regimen being developed by ImmunityBio for the treatment of non-small cell lung cancer (NSCLC). The regimen consists of nogapendekin alfa inbakicept (Anktiva; N-803), a first-in-class IL-15 receptor agonist complex that stimulates the proliferation and activation of CD8+ T cells and natural killer (NK) cells, combined with two immune checkpoint inhibitors: nivolumab (Opdivo), which targets the PD-1 receptor, and ipilimumab (Yervoy), which targets the CTLA-4 receptor. By combining a cytokine-based immune stimulator with checkpoint blockade, the therapy aims to overcome immune resistance and enhance anti-tumor activity. This triplet combination is currently being evaluated in the Phase 3 QUILT-2.023 clinical trial as a first-line treatment for patients with advanced or metastatic NSCLC.

Brand names: Anktiva + Opdivo + Yervoy
Other names: NAI + Opdivo + Yervoy

Targets

PDCD1 (Programmed cell death protein 1 receptor)IL2RB (IL-2 receptor beta chain)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)

Beyond the preview

Go deeper on nogapendekin alfa inbakicept + nivolumab + ipilimumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nogapendekin alfa inbakicept + nivolumab + ipilimumab.

Explore the full profile